## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

88888

In re Application of:

Roger Ariel Alberto et al

Serial No.:

10/707,994

Filed:

January 30, 2004

For:

Combination of Intercalating

Organometallic Complexes and Tumor Seeking Biomolecules for DNA Cleavage and Radiotherapy

System and Method of Use

Group Art Unit:

1642

Examiner:

Fetterolf, Brandon J.

Atty. Docket: 1292.1

TYHM:0039/SWA/STA

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 CERTIFICATE OF TRANSMISSION OR MAILING 37 C.F.R. 1.8

I hereby certify that this correspondence is being transmitted by facsimile to the United States Patent and Trademark Office in accordance with 37 C.F.R. § 1.6(d), or is being transmitted via the Office electronic filing system in accordance with 37 C.F.R. § 1.6(a)(4), or is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

December 20, 2007

Date

Helen Tinsley

Sir:

## INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. §§ 1.97(c) AND 1.98

In compliance with the duty of disclosure under 37 C.F.R. § 1.56(a), it is respectfully requested that this Information Disclosure Statement be entered and that the listed references be considered by the Examiner and made of record. Applicants note that, due to recent amendments to 37 C.F.R. § 1.98(a), copies of the listed domestic references are no longer required to be submitted to the Examiner.

In accordance with 37 C.F.R. § 1.97, this Information Disclosure Statement is not to be construed as a representation that a search has been made, as an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b), or as a representation that no other possibly material information, as defined in 37 C.F.R. § 1.56(b), exists.

12/27/2007 SDENBOB1 00000013 10707994

180.00 OP

01 FC:1806

Serial No. 10/707,994 Information Disclosure Statement Page 2

Furthermore, the references listed on the attached PTO/SB/08 Forms are not to be construed as an admission that these references qualify as prior art as to the above-referenced application or any related application. Rather, these references are being presented for the Examiner's consideration without prejudice to the right to demonstrate that any of these references do not qualify as prior art should the Examiner choose to apply any of these references.

The following information is listed on the attached PTO/SB/08 Forms in accordance with 37 C.F.R. §1.98. Any explanation of non-English language documents contained in this Information Disclosure Statement is believed to constitute a concise explanation of the relevance of the listed reference as it is presently understood by the individual designated in § 1.56(c) most knowledgeable about the content of the listed reference, in accordance with 37 C.F.R. § 1.98(a)(3).

In accordance with 37 C.F.R. §1.97(c) a fee of \$180.00 is due for the present Information Disclosure Statement. As noted in the attached Interview Summary, Amendment, and Response, the Commissioner is authorized to charge this fee to the credit card listed on the included PTO-2038.

Respectfully submitted,

Date: December 20, 2007

Nathan E. Stacy

Reg. No. 52,249 Fletcher Yoder

7925 FM 1960 W., Suite 330

Houston, TX 77070 (281) 970-4545